Browse treatments

…ve T cell repertoire, thus diminish the association of TAB with ICB benefit. Similar observations are made in two ICB clinical tria…

…and anti-CTLA4 (immune-check-point blockade, ICB), or NOX-A12 + ICB (combination). Immune cells from tumor and blood were analyzed …

…upporting metabolites such as butyrate as adjunct therapies for ICB immunotherapy.…

…s HCC aetiology influence responsiveness or prognosis following immunotherapy?…

…ting the CXCR4–CXCL12 axis, either alone or in combination with ICB, as a means to modulate the TME and overcome resistance.8At the…

…MR) tumours (<10%) are eligible for immune checkpoint blockade (ICB).Methods and analysis 15 026 CRC tumour samples were analysed a…

…binatorial approaches, including kinase inhibitors, can enhance ICB efficacy by modifying the otherwise ‘cold’ hepatic microenviron…

…us confers improved progression-free survival when treated with ICB…

…MIREG consistently and robustly predicted clinical benefit from ICB (average AUROC ≥ 0.74), outperforming established biomarkers in…

…al analysis of a longitudinally sampled MM patient treated with ICB revealed distinct resistance clones associated with different m…

…h tumors with epigenetic loss of MLH1 had superior OS with dual ICB compared to PD-1 monotherapy (64.5 vs 40.4 months; HR=0.60 [0.3…